MedTrace Logo

Transcutaneous Auricular Vagus Nerve Stimulation on Post-Herpetic Neuralgia

NCT07123987 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-03-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) in the treatment of patients with post-herpetic neuralgia (PHN). Participants will receive taVNS in addition to standard care. The study aims to determine whether taVNS can provide significant pain relief and improve quality of life in PHN patients.

Conditions

  • Post Herpetic Neuralgia (PHN)

Interventions

DEVICE

transcutaneous auricular vagus nerve stimulation (taVNS)

Use of the EV-906 device with TENS ear clips for transcutaneous auricular vagus nerve stimulation (taVNS), applied according to the study protocol, in addition to standard medical treatment for post-herpetic neuralgia. This device meets ISO 13485, FDA QSR, and CE standards

OTHER

traditional medical treatment for PHN

Standard medical treatment for post-herpetic neuralgia as per current clinical guidelines, without the application of taVNS device.

Sponsors & Collaborators

  • Mohamed Hosny Ismail Easa

    lead OTHER

Principal Investigators

  • Wafaa Hussein Borhan, PhD · Professor of Physical Therapy for Surgery Department, Faculty of Physical Therapy, Cairo University

  • Rofaida El Sayed El Naggar, MD · Lecturer of Dermatology, Kasr Alainy, Faculty of Medicine, Cairo University

  • Doaa Atef Aly, PhD · Lecturer of Physical Therapy for Surgery Department, Faculty of Physical Therapy, Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-07
Primary Completion
2026-09-09
Completion
2026-09-09

Countries

  • Egypt

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07123987 on ClinicalTrials.gov